One of the longest-running Alzheimer's research projects in the United States has received a major funding renewal from the National Institutes of Health, according to Washington University School of Medicine in St. Louis (WashU Medicine).

The National Institute on Aging, part of the NIH, has awarded $32 million over five years to the Healthy Aging and Senile Dementia program at WashU Medicine. The grant will support the study through 2031, its 45th year, the university reported.

The program was launched in the 1970s by neurologist Leonard Berg, who refused to accept memory loss in his older patients as a normal part of aging. Since then, it has enrolled more than 1,877 participants and is considered one of the longest-running longitudinal studies of Alzheimer's disease.

John C. Morris, the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, has led the program since 1998, when he took over from Berg. Morris said the study has fundamentally changed how scientists understand the disease.

"Forty years ago, we couldn't confirm Alzheimer's until after death, when the brain was studied under the microscope," Morris said in the announcement. "Because people have volunteered to come to us year after year and across multiple generations, we have learned the disease starts silently in the brain long before memory fails. Our goal now is to stop the disease process before it causes brain cells to die. Moreover, we need to be able to do that for all groups of people because Alzheimer's occurs in all races and ethnicities."

The renewed funding supports two key goals, according to WashU Medicine. First, the team will work to recruit a more diverse group of participants. Like most clinical research, the study has historically drawn mostly white, highly educated volunteers in good health. Since 1998, Morris has worked to increase the proportion of Black participants from 3% to 17%.

With the new funding, the team plans to expand a pilot study that enrolled about 40 people in north St. Louis to include 300 participants with varied education levels, income levels and health histories. Researchers will bring a mobile clinic into neighborhoods to collect data, blood and other tissue samples, and volunteers will be connected to health services if needed.

"A long history of mistrust in medical institutions as well as practical issues such as absence of transportation have discouraged many community members from participating in research at our medical center, so we're taking the research to the community," Morris said. "The community members who volunteer will give us their time, their blood samples and their trust, so we must give back to them."

Second, the researchers plan to track how patients in non-research clinical settings are responding to newly available Alzheimer's treatments. The goal is to understand the real-world impact of therapies that have shown promise in slowing Alzheimer's progression in some people, outside the controlled environment of clinical trials.

The program's earlier work laid the foundation for major advances. Berg and his colleagues developed the Clinical Dementia Rating, a tool Morris later refined that is now the global standard for determining whether dementia is present and its severity. Morris and his team also found that Alzheimer's-related brain changes could appear in people without memory symptoms, leading to the Adult Children Study in 2005, which follows middle-aged people who have a parent with Alzheimer's.

With the renewed funding, the program will also examine whether some Alzheimer's biomarkers differ between Black and white participants, which could indicate that diagnostic tools may not work equally well across racial groups.

Nicole Garrison, a pharmacist from Lake St. Louis and a research participant since 2025, said she takes part in the study because Black Americans are disproportionately affected by Alzheimer's yet are underrepresented in research. She has undergone cognitive tests, brain imaging, blood draws and spinal taps. She also advocates for wider access to blood-based Alzheimer's tests, which are far less invasive than brain scans or spinal taps.

"None of it guarantees I'll personally benefit," Garrison said. "That was never the point. Research is how we learn, how treatments improve and how hope becomes progress. I participate for my daughters, for families like mine, and as a Black woman who knows representation matters."

"Alzheimer's disease may run in my family, but this is where it runs out," she added.

For university students studying medicine, neuroscience, public health or related fields, the study offers a real-world example of how long-term research can reshape scientific understanding and clinical practice. The program's focus on community engagement and health equity also highlights how researchers are working to address historical disparities in clinical research.